ACS Nano · 2025 · 13 citations · 34 references
EngineeringBioengineeringCardiologyInflammationRegenerative MedicineTissue EngineeringCardiac RegenerationCardiac Tissue EngineeringInflammatory SignalingIschemic Heart DiseaseMesenchymal Stem Cell TherapyMesenchymal Stromal Cell TherapyCardiac Fibrosis ModulationCardiac Tissue RepairInflammation ResponsesMyocardial Infarction RepairMyocardial RepairMyocardial Tissue EngineeringSingle-cell Rna SequencingTransplantation
Mesenchymal stromal cell (MSC) therapy holds great promise for treating myocardial infarction (MI). However, the inflammatory and reactive oxygen species (ROS)-rich environment in infarcted myocardium challenges MSC survival, limiting its therapeutic impact. In this study, we demonstrate that chemical modification of MSCs with anti-VCAM1 and polydopamine (PD) significantly enhances MSC survival and promotes cardiac repair. Anti-VCAM1 modification facilitates MSC adhesion to inflamed tissue, ensuring MSC retention in the injured myocardium, while PD scavenges ROS surrounding MSCs, creating a conducive environment for cell transplantation. Our data indicate that chemically engineered MSCs effectively disrupt the inflammation-ROS cycle and modulate inflammation-related immune responses, thus improving MI microenvironments. Single-cell RNA sequencing of rat hearts reveals that treatment with engineered MSCs inhibits cardiac fibrosis by suppressing HB-EGF-EGFR signaling between anti-inflammatory macrophages and activated fibrillates. Ultimately, engineered MSCs demonstrate superior therapeutic efficacy in a rat model of MI. This study presents a straightforward, safe, and efficient chemical method for enhancing MSC therapy.
34
Xinyang Hu, Shan Ping Yu, Jamie L. Fraser et al. · Journal of Thoracic and Cardiovascular Surgery · 2008 · 623 citations · Full text
Tao‐Sheng Li, Ke Cheng, Konstantinos Malliaras et al. · Journal of the American College of Cardiology · 2012 · 460 citations · Full text